| # | Title | Journal | Year | Citations |
|---|
| 1 | DNMT1-interacting RNAs block gene-specific DNA methylation | Nature | 2013 | 446 |
| 2 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Blood | 2013 | 420 |
| 3 | Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia | Blood | 2012 | 394 |
| 4 | The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation | Blood | 2011 | 316 |
| 5 | Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemase–producingK. pneumoniae | Clinical Infectious Diseases | 2019 | 265 |
| 6 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia | Blood | 2015 | 197 |
| 7 | The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia | Haematologica | 2013 | 195 |
| 8 | Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial | Lancet Haematology,the | 2020 | 170 |
| 9 | Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls | European Journal of Epidemiology | 2013 | 141 |
| 10 | CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death | Blood | 2011 | 122 |
| 11 | Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia | Blood | 2013 | 113 |
| 12 | Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia | Leukemia | 2014 | 105 |
| 13 | Factors associated with mortality in bacteremic patients with hematologic malignancies | Diagnostic Microbiology and Infectious Disease | 2009 | 82 |
| 14 | Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy | Cancer Medicine | 2018 | 44 |
| 15 | Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia | ELife | 2014 | 43 |
| 16 | Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes | Experimental Hematology | 2016 | 42 |
| 17 | Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients | Leukemia | 2017 | 41 |
| 18 | Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) | Annals of Nuclear Medicine | 2016 | 37 |
| 19 | Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial | Clinical Cancer Research | 2019 | 34 |
| 20 | Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series | Annals of Hematology | 2018 | 32 |
| 21 | Patient‐reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes | Cancer | 2018 | 31 |
| 22 | CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma | Cancer Medicine | 2016 | 28 |
| 23 | Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone | Hematological Oncology | 2013 | 25 |
| 24 | FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET) | Annals of Nuclear Medicine | 2018 | 22 |
| 25 | Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 18 |
| 26 | Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization | Blood Cancer Journal | 2018 | 17 |
| 27 | PU.1 and CEBPA expression in acute myeloid leukemia | Leukemia Research | 2008 | 16 |
| 28 | SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms | Haematologica | 2014 | 16 |
| 29 | HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis | Leukemia and Lymphoma | 2019 | 16 |
| 30 | Lack of Infection with XMRV or Other MLV-Related Viruses in Blood, Post-Mortem Brains and Paternal Gametes of Autistic Individuals | PLoS ONE | 2011 | 16 |
| 31 | Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients | Oncotarget | 2017 | 14 |
| 32 | The prognostic role of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: a pilot study application of neural networks to predict time-to-event | Annals of Nuclear Medicine | 2021 | 13 |
| 33 | Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma | Oncotarget | 2018 | 12 |
| 34 | Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine | Leukemia Research | 2011 | 11 |
| 35 | Mental and physical well-being in oncology-hematology–unit personnel | Archives of Environmental and Occupational Health | 2018 | 11 |
| 36 | HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia | Cancers | 2019 | 11 |
| 37 | First case of breakthrough pneumonia due toAspergillus nomiusin a patient with acute myeloid leukemia | Medical Mycology | 2012 | 9 |
| 38 | Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience | Blood | 2014 | 9 |
| 39 | Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia | Expert Review of Hematology | 2017 | 8 |
| 40 | Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification | Blood | 2018 | 8 |
| 41 | In vitro cardiomyocyte differentiation of umbilical cord blood cells: crucial role for c-kit+ cells | Cytotherapy | 2015 | 7 |
| 42 | Heavy chain disease: our experience | Clinical Chemistry and Laboratory Medicine | 2017 | 7 |
| 43 | Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report | Infection | 2019 | 6 |
| 44 | The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years | Leukemia | 2022 | 6 |
| 45 | High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study | Journal of Fungi (Basel, Switzerland) | 2022 | 6 |
| 46 | Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy | Hematological Oncology | 2017 | 5 |
| 47 | Purging with chlorambucil to prevent infusion‐related reaction before obinutuzumab administration: A monocentric pilot experience | Hematological Oncology | 2019 | 5 |
| 48 | Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region | Frontiers in Oncology | 2020 | 5 |
| 49 | Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies | Experimental Hematology | 2014 | 4 |
| 50 | Flow cytometric analysis of human hemopoietic progenitor differentiation by assessing cell division rate and phenotypic profile | Methods in Cell Biology | 2001 | 3 |
